Education
About Us
Working with TipRanks
Follow Us
Tetralogic Pharmaceuticals Corp. (TLOG)
:TLOG
TLOG Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume107.58K
Average Volume (3M)N/A
Market Cap
$2.45K
Enterprise ValueN/A
Total Cash (Recent Filing)$5.89M
Total Debt (Recent Filing)$30.81M
Price to Earnings (P/E)―
Beta-8.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,465,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TLOG FAQ
What was Tetralogic Pharmaceuticals Corp.’s price range in the past 12 months?
Tetralogic Pharmaceuticals Corp. lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Tetralogic Pharmaceuticals Corp.’s market cap?
Tetralogic Pharmaceuticals Corp.’s market cap is $2.45K.
When is Tetralogic Pharmaceuticals Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tetralogic Pharmaceuticals Corp.’s earnings last quarter?
Currently, no data Available
Is Tetralogic Pharmaceuticals Corp. overvalued?
According to Wall Street analysts Tetralogic Pharmaceuticals Corp.’s price is currently Overvalued.
Does Tetralogic Pharmaceuticals Corp. pay dividends?
Tetralogic Pharmaceuticals Corp. does not currently pay dividends.
What is Tetralogic Pharmaceuticals Corp.’s EPS estimate?
Tetralogic Pharmaceuticals Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tetralogic Pharmaceuticals Corp. have?
Tetralogic Pharmaceuticals Corp. has 24,465,000 shares outstanding.
What happened to Tetralogic Pharmaceuticals Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tetralogic Pharmaceuticals Corp.?
Currently, no hedge funds are holding shares in TLOG
Company Description
Tetralogic Pharmaceuticals Corp.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Tetralogic Pharma (TLOG) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Biodexa Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Ocean Biomedical
―
Onconetix
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---